Log in

Relevant bibliographies by topics / Oxaliplatin / Journal articles

To see the other types of publications on this topic, follow the link: Oxaliplatin.

Journal articles on the topic 'Oxaliplatin'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Oxaliplatin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ain, Noor ul, Nusrat Bano, Anwar Ejaz Beg, Kamran Hameed, Talha Bin Fayyaz, and Rafia Sadaf. "HEMATOLOGICAL TOXICITY IN RATS;." Professional Medical Journal 24, no. 02 (February 14, 2017): 342–46. http://dx.doi.org/10.29309/tpmj/2017.24.02.525.

Full text

Abstract:

Objectives: Oxaliplatin causes hematological toxicities in clinical setting whichlimits its efficacy. The aim of this study is to investigate the therapeutic effects of Andrographispaniculata against hematological toxicity caused by oxaliplatin. Study design: Experimentalanimal study. Period: Study takes 8 month from March 2015 to Oct 2015. Setting: Dow universityanimal house. Method: Wistar albino male rats, divided into 3 equals groups (n=6): GroupN* was a control group (0.9% normal saline), Group NP0 was Oxaliplatin treated group andGroup NP1 was prophylactically treated with Andrographis paniculata followed by Oxaliplatinin order to assess the protective effects of Andrographis paniculata against the hematologictoxicity caused by Oxaliplatin. Results: Prophylactic treatment with Andrographis paniculata(NP1) significantly increases the levels of platelets and neutrophile count compared with thestandard (NP0) (p<0.01) and increases the RBCs count and levels of hemoglobin comparedwith the standard (NP0). Conclusion: Prophylactic treatment with Andrographis paniculata(NP1) was effective in reducing risk of thrombocytopenia, anemia and neutropenia associatedwith Oxaliplatin.

APA, Harvard, Vancouver, ISO, and other styles

2

Grothey, A., D. A. Nikcevich, J. A. Sloan, J. W. Kugler, P. T. Silberstein, T. Dentchev, D. B. Wender, H. E. Windschilt, X. Zhao, and C. L. Loprinzi. "Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 4025. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4025.

Full text

Abstract:

4025 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. We recently demonstrated the protective effect of CaMg against oxaliplatin-induced sNT as assessed by NCI-CTC (Nikcevich ASCO 2008). It is unclear, though, if CaMg reduced acute and/or chronic, cumulative sNT. Methods: 104 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a double-blinded manner. NCI-CTC, an oxaliplatin-specific sNT scale and patient-reported outcome (PRO) questionnaires were used to differentially assess the effect of CaMg on acute (effect on sNT on days 1–4 after oxaliplatin) and chronic sNT (area between curves over whole course of therapy). Results: A total of 102 pts (50 CaMg, 52 PL; 96 mFOLFOX6, 6 FOLFOX4) were available for analysis. Apart from a strong reduction in muscle cramps with CaMg (p=0.002), no difference was found between CaMg and PL in PRO with regard to items reflecting acute sNT (e.g. sensitivity to cold, swallowing of cold liquids, throat discomfort) on days 1–4 after oxaliplatin of any treatment cycle. In contrast, CaMg was able to significantly reduce cumulative sNT in form of numbness in fingers (p=0.02), impaired ability to button shirts (p=0.05), tingling in fingers (p=0.06), and muscle cramps over the course of therapy (p=0.01). Conclusions: In our phase III, placebo-controlled trial, CaMg was able to significantly reduce chronic, cumulative sNT related to oxaliplatin as evaluated by specific PRO questionnaires. No effect was noted on phenomena associated with acute sNT. CaMg can be recommended as neuroprotectant against oxaliplatin-related chronic sNT, oxaliplatin's dose-limiting toxicity. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

3

Pires, Lívia Márcia Vidal, and Patrícia Dos Santos Claro Fuly. "Mapeamento de fatores clínicos preditivos da neuropatia sensorial periférica induzida por oxaliplatina: revisão sistemática." Revista Recien - Revista Científica de Enfermagem 11, no. 35 (September 23, 2021): 382–97. http://dx.doi.org/10.24276/rrecien2021.11.35.382-397.

Full text

Abstract:

O objetivo deste estudo foi realizar um mapeamento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica induzida pela Oxaliplatina. Para tanto, foi realizada uma revisão sistemática, elaborada a partir das recomendações da diretriz PRISMA. A estratégia PICO também foi utilizada para formular a questão de pesquisa e orientar a busca nas bases de dados: PubMed, Embase, Scopus, BVS/IBECS e CINAHL. Foram selecionadas 26 publicações para análise final e inclusão na revisão. As publicações foram classificadas quanto ao nível de evidência e grau de recomendação, de acordo com o sistema JBI. Na análise das publicações foram mapeados 15 fatores preditivos, com maior destaque para a dose cumulativa de Oxaliplatina utilizada. O reconhecimento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica, independente da precocidade que possa ser feito, são importantes para a elaboração de estratégias mensuráveis no exercício do cuidado colaborativo e multidimensional.Descritores: Toxicidade, Quimioterapia Combinada, Enfermagem Baseada em Evidências, Cuidados de Enfermagem, Neoplasias Colorretais. Mapping of clinical factors predictive of oxaliplatin-induced peripheral sensory neuropathy: systematic reviewAbstract: The aim of this study was to map the predictive clinical factors of Oxaliplatin-induced Peripheral Sensory Neuropathy. For that, a systematic review was carried out, based on the recommendations of the PRISMA guideline. The PICO strategy was also used to formulate the research question and guide the search in the databases: PubMed, Embase, Scopus, BVS/IBECS and CINAHL. 26 publications were selected for final analysis and inclusion in the review. The publications were classified according to the level of evidence and degree of recommendation, according to the JBI system. In the analysis of the publications, 15 predictive factors were mapped, with greater emphasis on the cumulative dose of Oxaliplatin used. The recognition of clinical predictive factors for Peripheral Sensory Neuropathy, regardless of the precocity that can be done, are important for the development of measurable strategies in the exercise of collaborative and multidimensional care.Descriptors: Toxicity, Combined Chemotherapy, Evidence-Based Nursing, Nursing Care, Colorectal Neoplasms. Mapeo de factores clínicos predictivos de neuropatía sensorial periférica inducida por oxaliplatino: revisión sistemáticaResumen: El objetivo de este estudio fue mapear los factores clínicos predictivos de la Neuropatía Sensorial periférica inducida por oxaliplatino. Para ello se realizó una revisión sistemática, con base en las recomendaciones de la guía PRISMA. También se utilizó la estrategia PICO para formular la pregunta de investigación y orientar la búsqueda en las bases de datos: PubMed, Embase, Scopus, BVS/IBECS y CINAHL. Se seleccionaron 26 publicaciones para su análisis final e inclusión en la revisión. Las publicaciones se clasificaron según el nivel de evidencia y grado de recomendación, según el sistema JBI. En el análisis de las publicaciones se mapearon 15 factores predictivos, con mayor énfasis en la dosis acumulada de Oxaliplatino utilizada. El reconocimiento de factores clínicos predictivos de la Neuropatía Sensorial Periférica, independientemente de la precocidad que se pueda realizar, es importante para el desarrollo de estrategias medibles en el ejercicio de la atención colaborativa y multidimensional.Descriptores: Toxicidad, Quimioterapia Combinada, Enfermería Basada en Evidencias, Cuidado de Enfermera, Neoplasias Colorrectales.

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1378 (November 2011): 27. http://dx.doi.org/10.2165/00128415-201113780-00098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1384 (January 2012): 43. http://dx.doi.org/10.2165/00128415-201213840-00174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1385 (January 2012): 35. http://dx.doi.org/10.2165/00128415-201213850-00129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1388 (February 2012): 24. http://dx.doi.org/10.2165/00128415-201213880-00093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1389 (February 2012): 34. http://dx.doi.org/10.2165/00128415-201213890-00124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1390 (February 2012): 28–29. http://dx.doi.org/10.2165/00128415-201213900-00109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1390 (February 2012): 29. http://dx.doi.org/10.2165/00128415-201213900-00112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1391 (March 2012): 32. http://dx.doi.org/10.2165/00128415-201213910-00119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 714 (August 1998): 12. http://dx.doi.org/10.2165/00128415-199807140-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1161 (July 2007): 20. http://dx.doi.org/10.2165/00128415-200711610-00064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1166 (August 2007): 19. http://dx.doi.org/10.2165/00128415-200711660-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1174 (October 2007): 21–22. http://dx.doi.org/10.2165/00128415-200711740-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1180 (December 2007): 32. http://dx.doi.org/10.2165/00128415-200711800-00099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1187 (February 2008): 21. http://dx.doi.org/10.2165/00128415-200811870-00068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1188 (February 2008): 18–19. http://dx.doi.org/10.2165/00128415-200811880-00060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1189 (February 2008): 27–28. http://dx.doi.org/10.2165/00128415-200811890-00086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1191 (March 2008): 20. http://dx.doi.org/10.2165/00128415-200811910-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1192 (March 2008): 27. http://dx.doi.org/10.2165/00128415-200811920-00072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1194-1195 (March 2008): 28. http://dx.doi.org/10.2165/00128415-200811940-00102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1123 (October 2006): 15. http://dx.doi.org/10.2165/00128415-200611230-00045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1128 (November 2006): 15. http://dx.doi.org/10.2165/00128415-200611280-00048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1129 (November 2006): 16. http://dx.doi.org/10.2165/00128415-200611290-00055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1138 (February 2007): 21–22. http://dx.doi.org/10.2165/00128415-200711380-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1140 (February 2007): 17. http://dx.doi.org/10.2165/00128415-200711400-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1141 (March 2007): 17–18. http://dx.doi.org/10.2165/00128415-200711410-00061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1149 (April 2007): 19–20. http://dx.doi.org/10.2165/00128415-200711490-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1156 (June 2007): 20. http://dx.doi.org/10.2165/00128415-200711560-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1160 (July 2007): 24–25. http://dx.doi.org/10.2165/00128415-200711600-00068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1360 (July 2011): 29. http://dx.doi.org/10.2165/00128415-201113600-00099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1361 (July 2011): 31–32. http://dx.doi.org/10.2165/00128415-201113610-00111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1363 (August 2011): 31. http://dx.doi.org/10.2165/00128415-201113630-00122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1366 (August 2011): 24. http://dx.doi.org/10.2165/00128415-201113660-00090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 31–32. http://dx.doi.org/10.2165/00128415-201113680-00115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 32. http://dx.doi.org/10.2165/00128415-201113680-00117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 32. http://dx.doi.org/10.2165/00128415-201113680-00119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1370 (September 2011): 30. http://dx.doi.org/10.2165/00128415-201113700-00105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1371 (October 2011): 29. http://dx.doi.org/10.2165/00128415-201113710-00109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1374 (October 2011): 28. http://dx.doi.org/10.2165/00128415-201113740-00100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1375 (October 2011): 24. http://dx.doi.org/10.2165/00128415-201113750-00080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1375 (October 2011): 24. http://dx.doi.org/10.2165/00128415-201113750-00082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

L??vi, Francis, Gerard Metzger, Claire Massari, and Gerard Milano. "Oxaliplatin." Clinical Pharmacokinetics 38, no. 1 (January 2000): 1–21. http://dx.doi.org/10.2165/00003088-200038010-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Carlson, Robert. "Oxaliplatin." Inpharma Weekly &NA;, no. 1130 (March 1998): 3–4. http://dx.doi.org/10.2165/00128413-199811300-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 772 (October 1999): 10. http://dx.doi.org/10.2165/00128415-199907720-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 776 (November 1999): 10. http://dx.doi.org/10.2165/00128415-199907760-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 804 (June 2000): 11. http://dx.doi.org/10.2165/00128415-200008040-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 834 (January 2001): 9–10. http://dx.doi.org/10.2165/00128415-200108340-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 850 (May 2001): 10. http://dx.doi.org/10.2165/00128415-200108500-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!